BIOLASE Technology, Inc., a medical technology company focused on pain-free medical and dental procedures, announced today that it received approval for listing on NASDAQ's European operation, NASDAQ Europe, a subsidiary of The NASDAQ Stock Market, Inc. BIOLASE will begin trading on NASDAQ Europe on Sept. 18, 2002 under the same symbol it trades on NASDAQ, BLTI.
Federico Pignatelli, Chairman of the Board, stated, "We are pleased to be accepted for listing on NASDAQ Europe, having fulfilled their stringent requirements. We join 43 other listed companies, such as industry giants Microsoft, Apple, Cisco, Dell, Intel and Sun. This additional NASDAQ listing benefits BIOLASE with greater visibility to a large population of institutional and private European investors who are increasingly trading on NASDAQ Europe."
"In addition to the U.S., BIOLASE has a strong shareholder base in Europe," stated Jeffrey W. Jones, BIOLASE CEO and president. "As the level of interest in the Company increases, a European listing is a logical step. The forming of BIOLASE Europe, an ISO 9000 facility producing both Waterlase and LaserSmile systems, has recently strengthened the Company's international presence. With the strong growth, profitability, impressive patent and FDA clearance portfolios, innovative technology and a straightforward business model, BIOLASE is an excellent candidate for sophisticated institutional and European investors."
